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The paraaortic counterpulsation device is a round pumping chamber with 
one valveless opening 20 mm in diameter and a 100 ml stroke volume. The 
paraaortic counterpulsation device was implanted on the ascending aorta 
of three male patients with intractable cardiogenic shock. Patients were 
assisted for 4 hours and 8 and 54 days, respectively; the first patient died 
as a result of nonresponding peripheral vasodilation and the other two died 
of septic shock. The two patients who were assisted for 8 and 54 days were 
conscious and able to function in a limited manner during the mechanical 
assistance. Discontinuation of the mechanical support for a few seconds 
was followed by low systolic arterial pressure (30 to 60 mm Hg) and 
syncopal episodes. Biochemical tests and autopsy results in these patients 
showed no evidenee of blood cell destruction, thrombus formation, brain 
infarction, or other distal emboli. In conclusion, satisfactory hemodynamic 
effects, excellent biocompatibility, and simplicity of the implantation pro- 
cedure in these patients encourage the use of the paraaortic counterpulsa- 
tion device as a bridge to heart transplantation. (J THORAC CARDIOVASC 
SURG 1996;111:55-61) 
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T he high mortality rate of patients with cardio- genic shock and the limited number of donor 
hearts 1-7 necessitate the use of assisting devices that 
have the capacity of undertaking most or all the 
work of the failing hear t )  q7 The complexity of the 
existing devices and the attendant high risk and 
complicati~ns13, 16-18 stress the need for continua- 
tion of investigation for new developments. The 
paraaort ic ounterpulsation device (PACD) is a new 
high stroke volume counterpulsation device. 19-2° It 
has been more effective in the failing heart than the 
intraaortic balloon pump (IABP) when implanted 
on the abdominal aorta. 21 Its implantation on the 
ascending aorta was effective in restoring the hemo- 
dynamics  in~ severe experimental cardiogenic 
shock22, 23: and became ineffective only when the 
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systolic arterial pressure was low. It is noteworthy 
that a counterpulsation device is more effective 
when implanted on the ascending rather than on the 
abdominal aorta. 24 The biocompatibility of the 
PACD in chronic experiments was shown to be 
better than that of the total artificial heart. 25 In this 
report, the implantation procedure and the hemo- 
dynamic effect and biocompatibility of the PACD in 
its first clinical applications are evaluated. 
Patients and methods 
PACD. The PACD (Fig. 1) is a round pumping cham- 
ber connected by a screw-connector to a spiral poly- 
tetrafluoroethylene graft 3 to 5 cm in length with one 
valveless orifice 20 mm in diameter. It has a 100 ml stroke 
volume when fully inflated and an ejection fraction of 
65%. The air space of the device is separated by three 
polyurethane filaments from the blood space. It was made 
with the use of the same technique and materials used for 
the Utah Artificial Heart (Symbion, Inc., Salt Lake City, 
Utah). A gas conduit leads from the pumping chamber to 
the Datascope 82 driving system (Datascope Corp., 
Montvale, N.J.). This driving system pumps at a 7 to 8 Pi 
driving pressure and almost zero vacuum pressure. The 
zero vacuum pressure was obtained by means of a safety 
valve added on the Datascope 82 driving system. This 
valve was electrically adjusted to open during the vacuum 
phase of the driving system. The driving Datascope 82 
system was adjusted on the base of the electrocardiogram 
to provide aortic diastolic augmentation. During the sys- 
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Fig. 1. Schematic presentation of the PACD. 
tolic phase of the left ventricle, the pressure into the 
device was near zero, thus blood from the left ventrMe 
and the aorta entered the device; during the diastolic 
phase of the left ventricle, blood was ejected from the 
device into the ascending aorta. 
Implantation procedure. After midsternotomy, the 
chest was opened and the graft was anastomosed to the 
right lateral wall of the ascending aorta at a 30- to 45- 
degree angle with the proximal part of the aorta. The air 
conduit was placed subcutaneously and was brought out 
on the anterior lateral chest wall at the level of the seventh 
intercostal space. The gas conduit was connected to the 
intraaortic balloon driving system. The vacuum pressure 
was near zero, but for safety purposes an electrically 
triggering exit valve was placed and activated when the 
driving system was in the vacuum phase. The R wave was 
detected by means of a lead of the surface or the 
epicardial electrocardiogram, and the driving system was 
synchronized to provide aortic diastolic augmentation. 
Patients. Three men, 57, 32, and 33 years of age, had 
cardiogenic shock which was intractable to conventional 
treatment including the IABP and were assisted by the 
PACD for 4 hours and 8 and 54 days, respectively. 
Results 
Patient No. 1. A 57-year-old man underwent 
emergency coronary artery bypass grafting because 
of recent myocardial infarction and episodes of 
angina at rest after myocardial infarction. He re- 
ceived two vein grafts on the left anterior descend- 
ing coronary artery and the first diagonal branch. He 
was weaned from extracorporeal circulation with the 
assistance of the IABP, and high doses of adrenaline 
infusion (40 /xg/min) were given. He was assisted 
continuously with the IABP for 2 days, but higher 
doses of inotropic support were required to keep 
him alive. During this period he was clinically in 
cardiogenic shock with systolic arterial pressure less 
than 85 mm Hg, had a heart rate of more than 130 
beats/min, was totally anuric for the last 24 hours, 
and had an arterial oxygen tension around 63 mm 
Hg (inspired oxygen fraction = 80% and peak 
end-expiratory pressure = 10 cm H20 ). At that time 
the PACD was implanted to interrupt the vicious 
cycle of the shock. Anesthesia, induced to implant 
the PACD, resulted in intractable peripheral vaso- 
dilation; even higher doses of adrenaline infusion 
did not restore hemodynamics, and the patient died 
4 hours after PACD implantation. After the pa- 
tient's death, no clots were found within the device. 
Infections were not detected around the device or 
around its driving line. 
Patient No. 2. A 32-year-old man with a 6-month 
history of progressively impaired dyspnea nd ankle 
edema was ädmitted to our hospital because of in- 
tractable heart failure and recurrent syncopal epi- 
sodes caused by ventricular fibrillation. Two months 
before his last admission, while he was receiving 
medical treatment with digoxin 0.25 mg/day, enala- 
pril 5 mg/12 hours, furosemide 160 mg/day, and 
potassium chloride, he was evaluated for heart 
transplantation. His electrocardiogram showed nor- 
mal sinus rhythm, low voltage in limb leads, and 
nonspeeific ST-T changes. The chest roentgenogram 
showed an obvious eongestion and enlarged cardiac 
shadow. The eehocardiogräm showed a markedly 
dilated left ventriele (left ventricular end-diastolie 
dimension = 78 mm) and left atrium (57 mm), 
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regurgitation of the mitral and tricuspid valves, and 
markedly decreased contraction of the left and right 
ventricles. Ejection fraction was 9% by nuclear 
ventriculography. His hemodynamics were indica- 
tive of left and right ventricular failure (Table I), 
and his right ventricular biopsy specimen was indic- 
ative of cardiomyopathy. Forty days before his last 
admission he had pneumonia, nd during hospital- 
ization he had cardiogenic shock with pulmonary 
congestion, abdominal pain, and ankle edema re- 
quiring high doses of dobutamine (15 /xg/kg/min) 
plus dopamine (15 /xg/kg/min). During that period 
he also had recurrent syncopal episodes caused by 
ventricular fibrillation. The patient was transferred 
to our hospital to undergo mechanical ssistance as 
a bridge to heart transplantation. On admission he 
was found in cardiogenic shock with orthopnea, 
abdominal pain, generalized edema, and a large 
decubitus ulcer. The combination of high intrave- 
nous doses of furosemide and high doses of inotro- 
pic drugs initially stabilized the patient's condition, 
but on hospitalization day 5 he had cardiogenic 
shock requiring mechanical assistance with the 
IABP. Discontinuation of the IABP was necessary 
after 10 days of mechanical support because of 
severe leg ischemia, which was followed by relapse 
of the cardiogenic shock with mental deterioration 
and anuria. At that time the patient was not re- 
sponding to high doses of doputamine and dopa- 
mine, and adrenaline infusion was required to keep 
him alive. Finally, the PACD was implanted. Partial 
clamping of the ascending aorta during graft anas- 
tomosis did not affect he patient's hemodynamics. 
After the operation, normal hemodynamics and 
diuresis were restored. Heparine 1200 IU/hr was 
administered intravenously after the first 8 postim- 
plantation hours up to postimplantation day 3, and 
thereafter the patient received a low dose of aceno- 
coumarol to maintain a prothrombin time of 1.4 to 
1.6 times the control value. The patient was extu- 
bated 24 hours after implantation and was well, 
communicating, and capable of limited function 
during the period of mechanical ssistance. Here it 
must be pointed out that, 4 days before PACD 
implantation, blood cultures howed multiresistant 
Acinetobacter calcoaceticus. The same microorgan- 
ism was grown in the blood cultures on postimplan- 
tation day 3. He died on postimplantation day 8 of 
septic shock. No hemolysis or platelet destruction 
was detectable during the whole period of mechan- 
ical assistance with the device, and autopsy showed 
no evidence of either distal embolus in any organ or 
Table I. Right heart catheterization f the second 
patient (2 months before his last admission) and the 
third patient (hospitalization day 6) 
Patient 
Second Third 
Age (yr) 32 33 
Right atrial pressure, mean (mm Hg) 11 17 
Right ventricular pressure, systolic/ 05/10 58/15 
end-diastolic (mm Hg) 
Pulmonary artery pressure, systolic/ 65/34/40 58/28/46 
diastolic/mean (mm Hg) 
Pulmonary capillary wedge pressure, 33 33 
mean (mm Hg) 
A-Vo 2 difference (cm3%) 3 10.4 
Arterial blood pressure, systolic/dia- 90/70/78 105/ 
stolic/mean (mm Hg) 70/80 
Cardiac output (L/min) 5.8 2.3 
Systemic vascular resistance (IU 11.4 27.4 
Wood units) 
Pulmonary arterial vascular resis- 1.2 4.7 
tance (IU Wood units) 
A-Vo2, Arteriovenous oxygen difference. 
thrombus formation into the body of the PACD. No 
infections of the tissues around the device or the 
driving line were present. 
Patient No. 3. A 33-year-old man was admitted to 
our hospital because of orthopnea, bdominal pain, 
weakness, and ankle edema. The patient had been 
free of symptoms up to 2 years before admission 
when he was hospitalized for pulmonary edema. 
After initial improvement, he had exertional dyspnea 
that became progressively worse, and for 2 months 
before his current admission he had paroxysmal noc- 
turnal dyspnea, ankle edema, fatigue, and weakness. 
On admission the clinical examination showed a 
well-developed, well-nourished orthopneic male pa- 
tient in acute distress. Blood pressure was 90/50 mm 
Hg, pulse rate was 140 beats/min and regular, res- 
piration was 20 breaths/min, jugular venous pressure 
was estimated to be more than 20 cm H20, and the 
temperature was 38 ° C. He had no cyanosis. A sys- 
tolic low left parasternal heave was palpable, and 
the apical pulse was also palpable on the fifth and 
sixth intercostal spaces to the left of the midclavicu- 
lar line and was sustained and increased. Physical 
signs of left and right heart failure and mitral 
regurgitation were present. The electrocardiogram 
showed normal sinus rhythm, left ventricular hyper- 
trophy, and intraventricular conduction defect. 
Chest roentgenograms showed a markedly enlarged 
heart. The echocardiogram showed markedly di- 
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Fig. 2. Tracing of the aortic pressure, obtained from the 
third patient with the PACD, functioning on every heart 
beat for the first four cardiac cycles and cessation of its 
function after that, and the IABP, functioning on every 
other heart beat. It is obvious that the IABP alone was 
ineffective and that the simultaneous use of the two 
devices provided higher aortic diastolic augmentation 
than any of the devices alone. AOP, Aortic pressure; S, 
systolic pressure;/, aortic diastolic augmentation provided 
by the IABP; P, aortic diastoli c augmentation provided by 
the PACD; P+/, aortic diastolic augmentation provided 
by the PACD and the IABP. 
lated left (left ventricular end-diastolic dimension = 
78 mm) and right ventricles (right ventricular end- 
diastolic dimension -- 36 mm) and left atrium 
(44 mm), regurgitation of the mitral and tricuspid 
valves, and diffuse and markedly decreased contrac- 
tion of the left and right ventricular walls. Radio- 
nuclear ventriculography showed a left ventricular 
ejection fraction of 6%. Coronary arteriography 
before admission had shown normal coronary arter- 
ies and diffuse and markedly decreased contraction 
of the left ventricle with severe mitral regurgitation. 
The patient received high doses of diuretics (230 _+ 
290 mg/day, intravenous furosemide) and dobut- 
amine (8 _+ 3/xg/kg/min). After 6 days of intensive 
treatment his condition improved clinically, and he 
underwent right heart catheterization (Table I). On 
hospitalization day 11, patient was supported by 
mechanical assistance with the IABP because of 
cardiogenic shock. He responded with significant 
improvement, which lasted for 9 days, after which 
the patient again showed signs of progressive car- 
diogenic shock despite assistance with the IABP, 
high doses of dobutamine, and additional adminis- 
tration of high doses of dopamine. The use of 
adrenaline drip was necessary to keep the patient 
alive. The creatinine level increased to 3.6 mg/dl, 
and urea was 250 mg/dl, while potassium was 6.4 
mEq/L, and sodium was 120 mEq/L. At that time, 
on hospitalization day 21,the PACD was implanted. 
During the assistance with the IABP pump, heparin 
1200 IU/hr was administered intravenously and was 
continued to be administered on the same dose after 
Fig. 3. A chest roentgenogram of the third patient after 
implantation of the PACD seen on the right side of the 
cardiac shadow. The IABP is also seen. 
the implantation of the PACD. Partial clamping of 
the ascending aorta during graft anastomosis did not 
affect patient's hemodynamics. 
During the first 4 hours the patient showed im- 
pressive hemodynamic improvement with an in- 
crease of mean aortic pressure from 52 to 85 mm Hg 
and a urine output o 100 ml/hr starting from anuria. 
Six hours after the operation the course was com- 
plicated by massive mediastinal bleeding which re- 
sulted in oligemic shock. Heparin administration 
was discontinued for 12 hours. Thereafter, heparin 
was administered up to postimplantation day 3, and 
afterwards the patient received low-dose acenocou- 
marole to maintain a prothrombin time of 1.4 to 1.6 
times the control value. Normal hemodynamics 
were restored after 4 hours with blood transfusion 
and crystalloid fluid administration; however, the 
patient had acute renal insufficiency and later re- 
quired peritoneal dialysis which lasted for the rest of 
his clinical course. On postimplantation day 43 the 
patient had pneumonia nd, after that, septic shock; 
he died 54 days after PACD implantation. 
The patient was assisted for 3 days with two 
devices, the PACD and the IABP (Fig. 2). The 
IABP was withdrawn on postimplantation day 3 
(Fig. 3), and the patient was assisted only with the 
PACD thereafter (Fig. 4). During the 54 days of 
mechanical assistance, interruption of function of 
the PACD for a few seconds was followed by 
syncopal episodes with low systolic arterial pressure 
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Fig. 4. Upper tracing." Radial arterial pressure (RAP), obtained on the day after implantation from the third 
patient, with the PACD functioning as follows: (1) on every heart beat, (2) on every other heart beat, (3) 
on every third heart beat. Lower tracing: RAP, obtained on the day after implantation from the third 
patient, with the PACD functioning on every heart beat followed by temporary interruption. DP, Driving 
pressure; S, systolic pressure; P, aortic diästolic äugmentation provided by the PACD. 
(30 to 60 mm Hg) (Fig. 4). In this patient, because of 
the prominent right heart failure, the administration 
of inotropic agents was necessary to keep adequate 
hemodynamic conditions. The patient was able to 
communicate and had minimal function (e.g., he 
could eat and sit in a chair). 
No hdmolysis was detectable, and hematocrit 
value was 40% before device implantation, was 36% 
after the first week, and remained on the same level 
during the entire course of assistance with the 
PACD. Lactate dehydrogenase had not increased. 
Indirect bilirubin was within normal limits, and 
plasma-free hemoglobin was undetectable after the 
first post[mplantation week. 
Extensive autopsy showed a right lung infiltrate 
(lower lobe ). No evidence was found of distal em- 
bolus in:any organ (brain, kidneys, etc.) or of 
thrombus formation within the "cavity" of the 
PACD. The device was easily removed from its 
implanta{ion side, and no infections were detected 
on the tissues urrounding the device and the driving 
line. 
Discuss ion  
This article describes the initial clinical experi- 
ence with the PACD. Devices which perform on the 
same principles include the following: The IABP, 
which has become the most popular assisting device, 
the implanted mechanical auxiliary ventricle, and 
the dynamic aortic patch. 26' 27 With the exception of 
the IABP, the other devices are no longcr in clinical 
use. These devices required a major operation for 
their implantation, and the obtainable hemody- 
namic benefits were similar to those of the IABP. 
The implantation procedure of the PACD in 
these patients has proven to be a simple and fast 
procedure. The implantation was performed with 
partial clamping of the ascending aorta and required 
about 30 minutes from the time that the aorta was 
clamped until the device started assisting the pa- 
tient. The partial clamping of the aorta was not 
followed by hemodynamic compromise. Its hemody- 
namic effects, even when the device was implanted 
on the abdominal aorta, were superior to those of 
the IABP. 2~ A similar device implanted on the 
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brachiocephalic artery in sheep proved to have 
salutary hemodynamic effects greatly exceeding 
those of the IABP. 28 Furthermore, the implantation 
of the PACD on the ascending aorta is expected to 
provide further hemodynamic improvement. 22-z4 
However, this matter necessitates further investiga- 
tion. The biocompatibility of the PACD has been 
shown to be better than the total artificial heart in 
experimental animalsY In this limited clinical expe- 
rience the hemocompatibility was excellent accord- 
ing to the hematologic and biochemical tests. Au- 
topsy results were negative for infarctions on any 
organ or thrombus formation in the device. The 
absence of valves in the device may have accounted 
for these effects. The recommended anticoagulation 
therapy could be as follows: (1) intravenous dextran- 
40, 10% solution at the rate of 50 ml/hr, should be 
started 2 hours before implantation and continued 
for 12 hours after the implantation. Intravenous 
methylprednisolone (250 mg) should be adminis- 
tered to prevent potential anaphylactic reactions to 
dextran. (2) The device must be prefilled with 
heparinized (5000 IU) dextrose 5% before its con- 
nection to the graft. (3) When dextran is discontin- 
ued, continuous infusion of heparin 1200 IU/hr must 
be given for 3 days. (4) Thereafter, patients must be 
treated with aspirin 100 mg/day and acetocoumarole 
to maintain a prothrombin time of about 1.5 times 
of the control value. 
It is noteworthy that the effect of the PACD on 
human blood cells seems to be better than expected 
compared with that of the experimental nimal 
studies. This effect is probably due to higher throm- 
bogenicity of animals compared with human beings. 29 
These findings and the fact that two patients 
remained without anticoagulants forup to 12 hours 
leads to the assumption that anticoagulant therapy 
is probably not absolutely necessary for this device. 
On the other hand, the mechanical uxiliary ventri- 
cle, after its implantation i two patients, was not 
used further because of thromboembolism from the 
prosthesis, a6-27 Regarding the hemodynamic effects, 
it was impressive to note that PACD was able to 
restore hemodynamics and keep the patient alive for 
up to 54 days while the left ventricle without the 
mechanical support could not generate a systolic 
blood pressure higher than 30 to 60 mm Hg. Two of 
three patients, while assisted with the PACD, were 
conscious and able to communicate well, speak, and 
eat, and the patient with the longest survival was 
able to stand up and sit in a chair. The PACD 
assisted the failing left ventricle to a degree almost 
equal to that provided by other left ventricular assist 
devices. However, this device cannot ake over all of 
the work of the ventricle for more than a few 
minutes. 3° On the other hand, the total artificial 
heart and some ventricular assist devices can substi- 
tute the work of the heart. Some common problems 
of the ventricular assist devices and the total artifi- 
cial heart are the major operation required for their 
implantation, the technical challenge and the time 
required for insertion, the increased cost, and the 
high risk for thromboembolic episodes. The pres- 
ence of prominent right heart failure in the third 
patient required the administration of inotropic 
agents to preserve adequate hemodynamics. How- 
ever, in cases of severe biventricular failure with 
evidence of systemic ongestion and cardiogenic 
shock, the biventricular support systems are proba- 
bly more suitable. Implantation of the PACD in 
three patients and assistance for up to 54 days 
provided some evidence that it can overcome some 
of the problems of the ventricular assist devices and 
the total artificial heart. It also points out the stronger 
effect of large-volume counterpulsation versus the 
smaller volume achieved by the IABP. It seems that 
this device has a place in the armament of the left 
ventricular assist devices, and it may be preferable to 
other devices in cases of intractable heart failure or 
severe cardiogenic shock (systolic arterial pressure 
more than 50 to 60 mm Hg) with predominant impair- 
ment of the left ventricular function. The earlier in the 
patient's course the PACD is implanted, the better 
the outcome of the patient is expected to be because 
the patient will recover easier from the implantation 
procedure and the hemodynamic improvement will 
prevent the failure of other organs. 
The PACD implanted on the ascending aorta of 
three patients proved to be able to restore hemody- 
namics for up to 54 days, and its biocompatibility 
was excellent. These results howed the significance 
of using high stroke volume for the effectiveness of 
the counterpulsation technique and encourage the 
use of the PACD as a bridge to heart ransplantation. 
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